Calnexin is necessary for T cell transmigration into the central nervous system
Authors:
- Joanna JungJJJoanna Jung
- Paul EggletonPEPaul Eggleton
- Alison RobinsonARAlison Robinson
- Jessica WangJWJessica Wang
- Nick GutowskiNGNick Gutowski
- Janet HolleyJHJanet Holley
- Jia NewcombeJNJia Newcombe
- Elzbieta DudekEDElzbieta Dudek
- Amber M. PaulAPAmber M. Paul
- Douglas ZochodneDZDouglas Zochodne
- Allison KrausAKAllison Kraus
- Christopher PowerCPChristopher Power
Open Access
- 8 March 2018
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (5)
Abstract
In multiple sclerosis (MS), a demyelinating inflammatory disease of the CNS, and its animal model (experimental autoimmune encephalomyelitis; EAE), circulating immune cells gain access to the CNS across the blood-brain barrier to cause inflammation, myelin destruction, and neuronal damage. Here, we discovered that calnexin, an ER chaperone, is highly abundant in human brain endothelial cells of MS patients. Conversely, mice lacking calnexin exhibited resistance to EAE induction, no evidence of immune cell infiltration into the CNS, and no induction of inflammation markers within the CNS. Furthermore, calnexin deficiency in mice did not alter the development or function of the immune system. Instead, the loss of calnexin led to a defect in brain endothelial cell function that resulted in reduced T cell trafficking across the blood-brain barrier. These findings identify calnexin in brain endothelial cells as a potentially novel target for developing strategies aimed at managing or preventing the pathogenic cascade that drives neuroinflammation and destruction of the myelin sheath in MS.Keywords
Funding Information
- Canadian Institutes of Health Research (MOP-15291)
- Canadian Institutes of Health Research (MOP-15415)
- Canadian Institutes of Health Research (PS-153325)
This publication has 44 references indexed in Scilit:
- Incidence and prevalence of multiple sclerosis in Europe: a systematic reviewBMC Neurology, 2013
- Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)British Journal of Pharmacology, 2011
- Enhanced Clathrin-Dependent Endocytosis in the Absence of CalnexinPLOS ONE, 2011
- Blood–brain barrier breakdown as a therapeutic target in traumatic brain injuryNature Reviews Neurology, 2010
- Calnexin Deficiency Leads to DysmyelinationJournal of Biological Chemistry, 2010
- Regulation of Th17 Differentiation by Epidermal Fatty Acid-Binding ProteinThe Journal of Immunology, 2009
- The quality control of MHC class I peptide loadingCurrent Opinion in Cell Biology, 2008
- Endoplasmic reticulum stress in the absence of calnexinCell Stress and Chaperones, 2008
- Peroxiredoxin V in multiple sclerosis lesions: predominant expression by astrocytesMultiple Sclerosis Journal, 2007
- Calreticulin and calnexin in the endoplasmic reticulum are important for phagocytosisThe EMBO Journal, 2001